The firm is a U.S.-based venture capital investor focused on deep-tech companies developing innovative technologies across healthcare, life sciences, and artificial intelligence. The firm manages multiple investment funds and is expanding its investment activities, with approximately 40% of its upcoming fund targeted toward healthcare and life sciences and the remaining 60% focused on AI and AI infrastructure. The firm invests globally, with a strong concentration of portfolio companies in the United States and a particular emphasis on connecting innovative companies with commercialization opportunities in Southeast Asia.
The firm invests across healthtech, medical technology, biotechnology, and deep-tech innovations with applications in healthcare and life sciences. The firm is broadly disease-agnostic and evaluates technologies addressing a wide range of healthcare challenges. Areas of interest include AI-enabled healthcare solutions, innovative medical technologies, biotechnology platforms, and technologies that improve clinical research, healthcare delivery, and operational efficiency. The firm is particularly interested in companies with technologies that can benefit from international clinical validation, regulatory development, and commercial expansion.
From a company and management team perspective, the firm does not impose specific requirements regarding management team composition or company structure. The firm differentiates its investment approach through hands-on operational and commercialization support, particularly for companies seeking expansion into Asian healthcare markets. Through its regional partnerships and healthcare innovation network, the firm can facilitate access to clinical research opportunities, healthcare systems, regulatory expertise, and commercialization resources. The firm also supports portfolio companies with market entry strategies, payer and reimbursement navigation, distribution partnerships, and broader business development initiatives.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
